Clinical trials: Lipid Disorders
Essential Hypertension, Dyslipidemia
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia
The purpose of this study is to evaluate the efficacy and safety of combination of Fimasartan/Rosuvastatin in comparison to each component administered alone in patients with essential hypertension and dyslipidemia.
- Trial name
- NCT02166814
- Testing
- Fimasartan and Rosuvastatin, Fimasartan, Rosuvastatin
- Where
- 26 sites in South Korea
- Volunteers
- 140 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Dyslipidemia
Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia
A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients with Dyslipidemia
- Trial name
- NCT06955104
- Testing
- JW0108 + C2407
- Where
- South Korea
- Volunteers
- 145 people
- Sponsor
- JW Pharmaceutical
Dyslipidemias, Hypercholesterolemia
Serum Cholesterol Reduction Efficacy of Biscuit With Plant Stanol Ester
Efficacy of plant stanols as esters on LDL-cholesterol reduction is well documented. LDL-cholesterol lowering efficacy of the ingredient in a biscuit (providing 2 g plant stanols as esters per day) is less well known.
- Conditions
- Dyslipidemias, Hypercholesterolemia, Hyperlipidemias
- Trial name
- NCT02331043
- Testing
- Plant stanol ester
- Where
- Thailand
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Raisio Group
Hypercholesterolemia
Efficacy of a Red Yeast Rice Based Nutraceutical Plus Probiotic in Patients With Moderate Hypercholesterolemia
A randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy of a red yeast rice based nutraceutical (monacolin K 10 mg/dose) plus probiotic (Bifidobacterium longum BB536 ®), versus placebo, in patients…
- Trial name
- NCT02689934
- Testing
- Lactoflorene colesterolo
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- Montefarmaco OTC SpA
Fabry Disease
A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease
People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme.
- Trial name
- NCT00074984
- Testing
- Fabrazyme (agalsidase beta)
- Where
- 26 sites in United States, Canada and 4 more
- Volunteers
- 82 people
- Sponsor
- Genzyme, a Sanofi Company
Hypertension and Dyslipidemia
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(3)
- Trial name
- NCT05245084
- Testing
- CKD-386(3), D013, D326, D337
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Niemann-Pick Disease, Type C
Safety and Tolerability Study of VTS-270 in Pediatric Participants With Niemann-Pick Type C (NPC) Disease
This is a Phase-2, multicenter, multiple dose, open-label, 2-part evaluation study which will primarily assess the safety and tolerability of VTS-270 (2-hydroxypropyl beta-cyclodextrin [HP-β-CD]) in pediatric participants with…
- Trial name
- NCT03687476
- Testing
- VTS-270
- Sponsor
- Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company
Hyperlipidemia
Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation
The purpose of this study is to explore the effects of omega-3-acid ethyl esters (TAK-085) on vascular endothelial function when administered for 8 weeks, as measured by FMD, in patients with hyperlipidemia.
- Trial name
- Oasis Flow (NCT02824432)
- Testing
- TAK-085
- Where
- 4 sites in Japan
- Volunteers
- 37 people
- Sponsor
- Takeda
Hypercholesterolaemia
LATAM LOWERS LDL-C
This is an open label, patient-level 1:1 randomized clinical trial in a multi-country study aiming to evaluate the real-world impact of inclisiran + Usual Care (UC) vs UC alone on LDL-C lowering, patient-reported outcomes, and…
- Trial name
- NCT06501443
- Testing
- Usual care, KJX839
- Where
- 11 sites in Argentina, Brazil
- Volunteers
- 520 people
- Sponsor
- Novartis Pharmaceuticals
Severe Hypertriglyceridemia
The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL)
The purpose of this study is to investigate the effects of SC401B (ethyl esters of eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA] 2 (~1260 mg EPA+DHA), 4 (~2520 mg EPA+DHA) or 6 (~3780 mg EPA+DHA) capsules per day in…
- Trial name
- NCT01997268
- Testing
- SC401B 2 capsules, SC401B 4 capsules, SC401B 6 capsules
- Sponsor
- Sancilio and Company, Inc.
Healthy, NAFLD
Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers
This study is to evaluate the effect of food on the pharmacokinetics of a single dose of ASC41 tablet in healthy volunteers, comparing fasting and postprandial pharmacokinetic parameters of Tmax, Cmax, AUC0-t, AUC0-∞.
- Conditions
- Healthy, NAFLD, Hyperlipidemia
- Trial name
- NCT04692025
- Testing
- ASC41 tablet
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Hypertension, Dyslipidemia
Efficacy of Fixed-doses of Antihypertensive and Statin Drugs
The purpose of this study is to evaluate the efficacy of different fixed-dose combination of Viena II in treatment of hypertension and dyslipidemia.
- Trial name
- NCT03401580
- Testing
- Viena II 160/10, Viena II 190/10, Viena II 160/12
- Sponsor
- EMS
Overweight or Obesity
Probiotic Influence on Obesity-Related Lipidemia
This study aims to investigate the effects of Bifidobacterium breve BBr60 on key health indicators in overweight and obese adults.
- Trial name
- NCT06305650
- Testing
- Probiotic
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Heterozygous Familial Hypercholesterolemia
Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders
A study to assess safety and efficacy of evolocumab (AMG-145) in paediatric subjects aged 10-17 years diagnosed with heterozygous familial hypercholesterolemia.
- Trial name
- HAUSER-RCT (NCT02392559)
- Testing
- Evolocumab
- Where
- 66 sites in United States, Australia and 24 more
- Volunteers
- 158 people
- Sponsor
- Amgen
Hypercholesterolemia
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4
The primary objective of the study was to evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in…
- Trial name
- GAUSS-4 (NCT02634580)
- Testing
- Evolocumab, Ezetimibe
- Where
- 35 sites in Japan
- Volunteers
- 61 people
- Sponsor
- Amgen
Hypercholesterolemia
Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003
To assess the longer term safety, tolerability, and LDL C lowering efficacy after 52 weeks of additional treatment with LIB003 with subcutaneous (SC) dosing every 4 weeks (Q4W)
- Trial name
- NCT03847974
- Testing
- LIB003
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- LIB Therapeutics LLC
Cholesterol Ester Storage Disease(CESD), Lysosomal Acid Lipase Deficiency
An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype
This is a Natural History study to characterize key aspects of the clinical course of late onset Lysosomal Acid Lipase (LAL) Deficiency/ Cholesteryl Ester Storage Disease (CESD).
- Trial name
- NCT01528917
- Where
- 16 sites in United States, Canada and 6 more
- Volunteers
- 49 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hypercholesterolemia, Dyslipidemia
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults
To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults
- Trial name
- NCT07655960
- Testing
- Test Drug, Reference Drug
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- AJU Pharm Co., Ltd.
Hypercholesterolemia, Hypertriglyceridemia
Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)
The purpose of this study is to evaluate the cholesterol lowering effectiveness and safety of two investigational drugs in patients with mixed hyperlipidemia (high cholesterol and high triglycerides).
- Trial name
- NCT00092560
- Testing
- MK0653, ezetimibe, Comparator: fenofibrate monotherapy
- Volunteers
- 587 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Effect of the Consumption of a Fermented Milk Enriched With Plant Sterols (Spain)
The purpose of this study is to investigate the cholesterol lowering effect of a drinkable low fat fermented milk enriched with plant sterol after 3 and 6 weeks in mildly hypercholesterolemic subjects treated or not by statins.
- Trial name
- NCT01600820
- Testing
- 1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit, 2- Low fat drinkable fermented dairy product enriched with 2.0g of plant sterol (as free equivalent) per unit, 3- Low fat drinkable fermented dairy product without plant sterols(control)
- Where
- Spain
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Danone Spain
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.